In The News

In Law360, Global Team Examines How Distributors Expose Health and Life Sciences Companies to FCPA Risks

Practices: Health Care, Life Sciences, Litigation, Government Enforcement, Business & Commercial Litigation, China Life Sciences, Anti-Corruption / International Risk, Asia Pacific, Digital Health, Technology, Media & Telecommunications, Risk Management

A cross-border team examined how third-party distributors can expose health care and life sciences companies with operations in the U.S. and abroad to increased liability and risks to the U.S. Foreign Corrupt Practices Act and other nations’ anti-corruption laws in an August 14 Law360 article.

The article was co-authored by litigation & enforcement partner Mimi Yang (Hong Kong), health care counsel Alison Fethke (Chicago), litigation & enforcement associate Tina Yu (London & Hong Kong), and corporate associate Grace Kim (Boston).

The authors address enforcement of anti-corruption laws and improper third-party actions, and guidance for health care and life sciences companies’ compliance programs.

Cookie Settings